OpenEvidence Valuation Soars to $12 Billion as AI Clinician Tool Gains Traction

In a significant show of investor confidence, the clinical decision-support company OpenEvidence has seen its valuation double to $12 billion. The Massachusetts-based firm, which provides an AI-powered platform for medical professionals, secured the new funding in a round led by Thrive Capital and DST Global.

The platform, often informally described as a specialized tool for physicians, allows doctors to query the latest medical research, guidelines, and clinical data in real time. It is designed to integrate with hospital workflows, aiming to reduce administrative burdens and support complex diagnostic processes.

This substantial capital infusion arrives as the healthcare sector continues to prioritize technological efficiency. The funding is earmarked for expanding OpenEvidence's engineering team and accelerating the development of new features focused on specialized care areas. Company executives indicate a portion will also support efforts to navigate the evolving federal health policy environment under the Trump administration, which began its term in 2025.

Industry observers note the valuation jump reflects a broader trend of targeted AI applications achieving substantial market traction, moving beyond generalized tools to solve specific, high-stakes professional challenges. With this latest round, OpenEvidence solidifies its position as a major force in the competitive health-tech field as it moves through 2026.

Source: CNBC